Krishna Institute of Medical Sciences reported a 35% year-on-year surge in consolidated operating revenue to ₹11,795 million for the quarter ended June 30, 2026 (Q1FY27), driven by strong patient volume growth and the integration of new hospital assets. While consolidated net profit attributable to owners declined 56% year-on-year to ₹374 million due to higher operational costs from expansion, the group’s EBITDA rose 20% to ₹2,398 million. The results were approved by the Board on August 3, 2026, following a limited review by statutory auditors S.R. Batliboi & Associates LLP.

Financial Performance Highlights

The company’s standalone revenue from operations grew 29% year-on-year to ₹4,836 million. On a consolidated basis, total income reached ₹11,959 million. EBITDA expanded by 10.9% quarter-on-quarter to ₹2,398 million, reflecting improved operational leverage in mature units. However, profit before tax (PBT) fell 50.2% year-on-year to ₹566 million, impacted by the statutory impact of new Labour Codes (₹74 million in Q4FY26 vs current period adjustments) and fair valuation losses on call options. Consolidated net profit stood at ₹374 million, down from ₹850 million in Q1FY26.

Operational Growth and Volume Metrics

Patient volumes drove the top-line growth, with inpatient (IP) admissions rising 26.6% year-on-year to 72,493 and outpatient (OP) visits increasing 28.5% to 658,617. Average Revenue Per Occupied Bed (ARPOB) increased 9.7% to ₹47,200, while Average Revenue Per Patient (ARPP) rose 6.8% to ₹163,573. The group’s bed capacity expanded to 7,459 beds, with operational beds reaching 5,639. Occupancy rate was 49.0%, slightly down from 52.5% in Q4FY26, as new units in Kerala and Maharashtra ramped up.

Regional Performance and New Units

Telangana remained the largest contributor, generating ₹6,235 million in revenue with an EBITDA margin of 29.5%. Andhra Pradesh contributed ₹2,634 million in revenue. Newer markets showed early traction: Kerala units generated ₹776 million in revenue with a 9.7% EBITDA margin, while Maharashtra units posted ₹1,504 million in revenue with a 7.5% EBITDA margin. Karnataka units continued to face headwinds, reporting an EBITDA loss of ₹192 million.

What the Numbers Show

The divergence between robust revenue growth (+35%) and declining net profit (-56%) highlights the capital-intensive nature of KIMS’ expansion strategy. While EBITDA growth (+20%) confirms operational efficiency in core units, the bottom line is pressured by initial setup costs, higher finance expenses, and non-controlling interest impacts in newly acquired or managed facilities. The ramp-up of O&M units like Kompally and Guntur, which are already EBITDA positive, suggests improving returns on recent investments.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE967H01025/03c9625b-d64b-4271-bdc4-2f62ac282f26.pdf

Krishna Institute of Medical Sciences Limited will host a conference call with analysts and investors on Tuesday, August 4, 2026, at 10:00 AM IST. The discussion will focus on the company's business strategy and future outlook following the declaration of its Q1FY27 financial results. This engagement provides stakeholders with direct access to management for insights into operational performance and strategic direction.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to the Bombay Stock Exchange Ltd and the National Stock Exchange on July 28, 2026. The call is being hosted by IIFL Capital, which has circulated the invitation details to market participants.

Key Management Participants

Key management personnel scheduled to participate in the conference call are listed below. Their presence ensures that both strategic and financial aspects of the Q1FY27 performance will be addressed comprehensively.

Dial-In Details

The conference call is accessible via toll-free numbers for both domestic and international participants. The access details are provided below.

A Diamond Pass registration is also available for enhanced access. For further information regarding the conference call, investors may contact Rahul Jeewani, Naman Bagrecha, Aman Goyal, or Vighnesh Indure at IIFL Capital. The company secretary and compliance officer, Dr. Nagajayanthi J. R., signed the disclosure document, confirming the accuracy of the intimation.